頁籤選單縮合
題名 | 治療骨質疏鬆症的新藥--Denosumab=Denosumab--A New Therapy for Osteoporosis |
---|---|
作者 | 施雅分; 廖淑貞; 蔡玉娟; 簡素玉; | 書刊名 | 藥學雜誌 |
卷期 | 29:1=114 2013.03[民102.03] |
頁次 | 頁114-118 |
分類號 | 418.2183 |
關鍵詞 | 骨質疏鬆症; Denosumab; RANKL; Receptor activator of nuclear factor kappa B ligand; Osteoporosis; |
語文 | 中文(Chinese) |
中文摘要 | Denosumab 為一具全新作用機轉用來治療停經後婦女具骨折高風險性之骨質疏鬆症的藥品,亦為一種人類單株抗體製劑,會與 RANKL (Receptor Activator of Nuclear Factor Kappa B Ligand) 結合,抑制 RANKL 和破骨細胞的結合,避免骨質的流失,因而增加骨骼骨質密度。Denosumab 有明顯降低停經後婦女之骨折風險的療效,包括新脊椎骨折、髖骨骨折及非脊椎骨折發生率,其為每6個月皮下注射60 mg,方便使用,亦可以改善病人的順從性。 |
英文摘要 | Denosumab is a new option for the treatment of postmenopausal osteoporosis in women with high fracture risk. Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor kappa B Ligand that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. This agent lowered risk for spine, hip, and nonvertebral fractures. The recommended dose is 60 mg every 6 months as a subcutaneous, thus improving patient adherence. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。